Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMA) was the recipient of a large drop in short interest in January. As of January 31st, there was short interest totalling 24,040,000 shares, a drop of 6.2% from the January 15th total of 25,640,000 shares. Currently, 23.0% of the company’s stock are short sold. Based on an average trading volume of 4,330,000 shares, the days-to-cover ratio is presently 5.6 days.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HUMA. SG Americas Securities LLC purchased a new stake in Humacyte during the third quarter worth about $174,000. Wealth Effects LLC purchased a new stake in Humacyte during the third quarter worth about $349,000. Private Advisor Group LLC boosted its holdings in Humacyte by 1.8% during the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after buying an additional 6,510 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Humacyte by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after buying an additional 8,965 shares in the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new stake in Humacyte during the third quarter worth about $75,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Tuesday, January 21st. HC Wainwright restated a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Finally, Benchmark lifted their price objective on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Down 0.3 %

Shares of Humacyte stock opened at $3.91 on Tuesday. Humacyte has a 52-week low of $2.81 and a 52-week high of $9.97. The company’s 50-day simple moving average is $4.47 and its 200-day simple moving average is $5.23. The firm has a market cap of $492.11 million, a price-to-earnings ratio of -2.92 and a beta of 1.30.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.